Epidemiology and management of cryptococcal meningitis: Developments and challenges

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 4, 2008, Pages 551-560

  Pukkila Worley, Read ^a   Mylonakis, Eleftherios ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amphotericin B; Cryptococcus gattii; Cryptococcus neoformans; Flunconazole; Fungal infection; HIV infection; Posaconazole; Voriconazole

Indexed keywords

ACETAZOLAMIDE; ALBACONAZOLE; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; VORICONAZOLE; ANTIFUNGAL AGENT;

ADD ON THERAPY; BRAIN VENTRICLE PERITONEUM SHUNT; CEREBROSPINAL FLUID CULTURE; CEREBROSPINAL FLUID DRAINAGE; CERVICAL LYMPHADENOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; EPIDEMIC; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION SENSITIVITY; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; LYMPHADENITIS; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; NONHUMAN; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SPECIES COMPARISON; SUPERINFECTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AIDS RELATED COMPLEX; DRUG ADMINISTRATION; HYDROCEPHALUS; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PATIENT SELECTION; PRACTICE GUIDELINE; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROCEPHALUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MENINGITIS, CRYPTOCOCCAL; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 40649118980     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.551     Document Type: Review

References (68)

1. Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 2002;51(4):804-6
2. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999;37(3):838-40
3. Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997;176(3):632-6
4. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003;36(6):789-94
5. Bekondi C, Bernede C, Passone N, et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis 2006;10(5):387-95
6. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000;14(10):1401-7
7. Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002;34(9):1251-8
8. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002;16(7):1031-8
9. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77(914):769-73
10. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001;33(5):690-9
11. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001;7(3):375-81
12. Pappas P, Patel R, Hadley S, et al. Cryptococcosis in transplant recipients: an analysis of 102 subjects. 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA; 2004
13. Kontoyiannis DP, Peitsch WK, Reddy BT, et al. Cryptococcosis in patients with cancer. Clin Infect Dis 2001;32(11):E145-50
14. Dromer F, Mathoulin S, Dupont B, et al. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis 1996;23(1):91-6
15. Tortorano AM, Viviani MA, Rigoni AL, et al. Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy. Mycoses 1997;40(7/8):297-302
16. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the Crypto A/D Study. PLoS Med 2007;4(2):E21
17. Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host-and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000;31(2):499-508
18. Kidd SE, Hagen F, Tscharke RL, et al. A rate genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004;101(49):17258-63
19. Fraser JA, Giles SS, Wenink EC, et al. Same-Sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005;437(7063):1360-4
20. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):710-8
21. Van Der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immnunodeficiency syndrome. National Institute of Allergy And Infectious Diseases Mycoses Study Group And AIDS Clinical Trials Group. N Engl J Med 1997;337(1):15-21
22. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326(12):793-8
23. Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999;28(1):82-92
24. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363(9423):1764-7
25. Schwarz P, Dromer F, Lortholary O, Dannaoui E. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother 2003;47(10):3361-4
26. Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 2006;50(1):113-20
27. Schwarz P, Janbon G, Dromer F, et al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2007;51(1):383-5
28. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006;15(6):579-602
29. Chandenier J, Adou-Bryn KD, Douchet C, et al. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004;23(6):506-8
30. Miller JL, Schell WA, Wills EA, et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48(2):384-7
31. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, Baro-Tomas T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005;43(6):505-10
32. Perkins A, Gomez-Lopez A, Mellado E, et al. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neofarmans var. neoformans. J Antimicrob Chemother 2005;56(6):1144-7
33. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida Spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48(3):201-5
34. Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG. In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis 2000;19(4):317-9 35 Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56(4):745-55
35. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000;182(6):1791-5
36. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006;43(8):1060-8
37. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 2005;49(7):2851-6
38. Bicanic T, Wood R, Bekker LG, et al. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005;5(9):530-1
39. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45(1):76-80
40. Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006;43(8):1069-73
41. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19(4):741-5
42. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998;26(6):1362-6
43. Nguyen MH, Najvar LK, Yu CY, Graybill JR. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41(5):1120-3
44. Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996;22(2):322-8
45. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991;324(9):580-4
46. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28(2):291-6
47. Mussini C, Pezzotti P, Miro JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an International Observational Study. Clin Infect Dis 2004;38(4):565-71
48. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003;36(10):1329-31
49. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30(1):47-54
50. Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, DC: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005;40(3):477-9
51. Patel S, Lederman E, Wallace M. Acetazolamide therapy and intracranial pressure. Clin Infect Dis 2003;36(4):538
52. Newton PN, Thai Le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002;35(6):769-72
53. Tang LM. Ventriculoperitoneal shunt in cryptococcal meningitis with hydrocephalus. Surg Neurol 1990;33(5):314-9
54. Chan KH, Mann KS, Yue CP. Neurosurgical aspects of cerebral cryptococcosis. Neurosurgery 1989;25(1):44-7
55. Park MK, Hospenthal DR, Bennett JE. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999;28(3):629-33
56. Liliang PC, Liang CL, Chang WN, et al. Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients. Clin Infect Dis 2003;37(5):673-8
57. Chander J, Mukherjee KK, Lehl SS. Chronic granulomatous meningoencephalitis caused by Cryptococcus neoformans var. gattii in an immunocompetent patient - a case report. Sixth International Conference on Cryptococcus & Cryptococcosis (ICCC). Boston, MA, USA; 2005
58. Shelburne SA III, Darcourt J, White AC, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40(7):1049-52
59. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-asaociated cryptococcosis in France. AIDS 2005;19(10):1043-9
60. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19(4):399-406
61. King MD, Perlino CA, Cinnamon J, Jernigan JA. Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy. Int J STD AIDS 2002;13(10):724-6
62. Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis 2005;40(12):1756-61
63. Baddour LM, Perfect JR, Ostrosky-Zeichner L. Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. Clin Infect Dis 2005;40(Suppl 6):S409-13
64. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26(6):1383-96
65. Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22(2):315-21
66. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (Ambisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11(12):1463-71
67. Hamill RJ, Sobel J, El-Sadr W, et al. Randomized double-blind trial of ambisome (Liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1999
68. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21(5):1145-53